POU2F3 and small cell lung carcinoma: FAK variants were present in 65 (95.6%) of 68 ASCL1+ SCLCs, 45 (90%) of 50 NEUROD1+ SCLCs, 6 (50%) of 12 POU2F3+ SCLCs, and 3 (12.5%) of 24 YAP+ SCLCs (Fig. 6c, Supplementary Table 12), indicating that FAK splicing variants were associated mainly with the ASCL1+ and NEUROD1+ SCLC subtypes.